Published on Jun 07, 2017
The Life Sciences sector, covering pharmaceutical and clinical innovation and technology is, according to a Times survey “providing sinew to the economy” and is one of the “jewels in the crown” of the UK economy.
2017 is being predicted as being another strong year and the sector received so-called ‘star billing’ – in the Great Repeal Bill: White Paper published last month – as one of twelve negotiating objectives for exiting the EU, including making the UK “one of the best places in the world for science and innovation”, with a desire to “continue to collaborate with Europe on scientific initiatives”.
There is also, the survey continues, “great hope that device, monitors and systems driven by artificial intelligence can energise diagnostic and preventative measures so that the ruinous surge of non-communicable diseases (eg cardiovascular diseases, cancers, respiratory diseases and diabetes) can be arrested.
The next government, according to Mike Thompson, CEO of the Association of the British Pharmaceutical Industry, “ must have a clear strategy to grow the UK’s status as a world leader in innovation and access to medicines”.
Just as well then, that the current prime minister is quoted as saying “it is hard to think of an industry of greater strategic importance to Britain than its pharmaceutical industry”. Management Forum, part of the Falconbury group, could not agree more!
Photo by rawpixel on Unsplash
Published on Jun 07, 2017 by Neil Thomas